Display options
Cite
Mozetic V, Freitas CG, Riera R. Statins and Fibrates for Diabetic Retinopathy: Protocol for a Systematic Review. JMIR Res Protoc. 2017;6(2):e30doi: 10.2196/resprot.6650.
Mozetic, V., Freitas, C. G., & Riera, R. (2017). Statins and Fibrates for Diabetic Retinopathy: Protocol for a Systematic Review. JMIR research protocols, 6(2), e30. https://doi.org/10.2196/resprot.6650
Mozetic, Vania, et al. "Statins and Fibrates for Diabetic Retinopathy: Protocol for a Systematic Review." JMIR research protocols vol. 6,2 (2017): e30. doi: https://doi.org/10.2196/resprot.6650
Mozetic V, Freitas CG, Riera R. Statins and Fibrates for Diabetic Retinopathy: Protocol for a Systematic Review. JMIR Res Protoc. 2017 Feb 22;6(2):e30. doi: 10.2196/resprot.6650. PMID: 28228373; PMCID: PMC5343211.
Copy Download .nbib Format: NLM
Share it on

JMIR Res Protoc. 2017 Feb 22;6(2):e30. doi: 10.2196/resprot.6650.

Statins and Fibrates for Diabetic Retinopathy: Protocol for a Systematic Review.

JMIR research protocols

Vania Mozetic, Carolina Gomes Freitas, Rachel Riera

Affiliations

  1. Universidade Federal de Sao Paulo, Sao Paulo, Brazil.

PMID: 28228373 PMCID: PMC5343211 DOI: 10.2196/resprot.6650

Abstract

BACKGROUND: Diabetic retinopathy (DR) is a common microvascular complication of diabetes mellitus, and more than 75% of patients who have had diabetes for more than 20 years will have some degree of DR. This disease is highly destructive to self-esteem and puts a high burden on public health and pension systems due to the effects that it has on people of working age. The current mainstay of treatment is laser photocoagulation, which causes impairment of vision and discomfort to patients. Thus, finding a systemic drug that could act on all microcirculation and prevent direct manipulation of the eyes would be highly desirable.

OBJECTIVE: To assess the efficacy and safety of the drugs in the statin and/or fibrate groups for the prevention and treatment of DR.

METHODS: In this systematic review, we will select randomized controlled trials of fibrates or statins used for the treatment or prevention of DR. Our search strategy will include free text terms and controlled vocabulary (eg, MeSH, Emtree) for, "diabetic retinopathy", "statins", "fibrates", "hypolipidemic agents", and for drugs from both groups. Databases that will be used include Medical Literature Analysis and Retrieval System/PubMed, Embase, Cochrane Central Register of Controlled Trials, Latin American and Caribbean Center on Health Sciences Information, Clinicaltrials.gov, World Health Organization International Clinical Trials Registry Platform, and OpenGrey, and we will not have language or date limits. Two review authors will independently select eligible studies and assess the risk of bias using the Cochrane Collaboration's tool. We will report structured summaries of the included studies and, if possible, conduct meta-analyses.

RESULTS: This is a protocol for a systematic review, therefore results are not available. We registered a short version of this protocol before progressing in the review and we are currently in the process of selecting the studies for inclusion.

CONCLUSIONS: Intensive glucose control and lowering blood pressure and lipids are mechanisms that protect macrocirculation in diabetic patients. Both macrovascular and microvascular events in diabetic patients appear to have a common pathway, starting with endothelial injury. Thus, prevention and treatment of microvascular events may benefit from the same interventions. In the review for which we have written this protocol, we will assess whether the use of lipid-lowering oral drugs of the statin and/or fibrate groups may prevent and/or retard progression of DR, with the added benefit of preserving visual acuity.

TRIAL REGISTRATION: PROSPERO CRD42016029746.

©Vania Mozetic, Carolina Gomes Freitas, Rachel Riera. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 22.02.2017.

Keywords: diabetic retinopathy, hypolipidemic agents, hydroxymethylglutaryl-CoA reductase inhibitors, fibric acids, ETDRS, HMG-CoA reductase inhibitors

References

  1. Lancet. 2007 Nov 17;370(9600):1687-97 - PubMed
  2. Am J Med. 1999 Jul;107(1):45-51 - PubMed
  3. Br J Ophthalmol. 1963 Nov;47:666-72 - PubMed
  4. Ophthalmology. 1991 May;98(5 Suppl):741-56 - PubMed
  5. Ophthalmology. 2003 Sep;110(9):1677-82 - PubMed
  6. Syst Rev. 2015 Jan 01;4:1 - PubMed
  7. Semin Ophthalmol. 2016;31(1-2):10-8 - PubMed
  8. Retina. 2007 Sep;27(7):816-24 - PubMed
  9. Diabetes. 1968 Jul;17(7):458-67 - PubMed
  10. Diabetes Care. 2016 Jul;39(7):1089-100 - PubMed
  11. Diabetes. 1991 Apr;40(4):405-12 - PubMed
  12. Cochrane Database Syst Rev. 2014 Feb 14;(2):CD009122 - PubMed
  13. Cochrane Database Syst Rev. 2015 Jan 31;1:CD006127 - PubMed
  14. Curr Neurovasc Res. 2006 Feb;3(1):73-7 - PubMed
  15. Br J Ophthalmol. 1985 Jan;69(1):15-8 - PubMed
  16. Doc Ophthalmol. 1980 Apr 15;48(2):363-71 - PubMed
  17. Am J Med. 1981 Feb;70(2):325-30 - PubMed
  18. Arq Bras Endocrinol Metabol. 2008 Aug;52(6):940-50 - PubMed
  19. JAMA Ophthalmol. 2015 May;133(5):503-10 - PubMed
  20. Diabetes. 1969 May;18(5):285-91 - PubMed
  21. Cochrane Database Syst Rev. 2014 Nov 24;(11):CD011234 - PubMed
  22. Trans Ophthalmol Soc U K. 1974 Jul;94(2):554-62 - PubMed

Publication Types